Fecal Immunochemical Test
Patients with negative FIT results in upper range still at risk for advanced neoplasia
Among patients with negative fecal immunochemical tests, those with values in the upper range demonstrated higher risk for advanced neoplasia vs. those in the lower range, according to data in Annals of Internal Medicine.
ColoSense detects CRC, advanced adenomas with sensitivities of 94%, 46%
The ColoSense multitarget stool RNA test demonstrated high sensitivity for detection of colorectal cancer and advanced adenoma, notably in individuals aged 45 to 49 years, according to data in JAMA.
Prevalence of sessile serrated lesions more than 6% among veterans after positive FIT
VANCOUVER, British Columbia — Predictors of sessile serrated lesions among veterans who underwent colonoscopy within 12 months of a positive fecal immunochemical test included older age, obesity and smoking, according to a presenter.
Sensitivity of next-generation Cologuard in precancer detection ‘numerically exceeded’ FIT
VANCOUVER, British Columbia — A next-generation, multitarget stool DNA test detected colorectal cancer with 94% sensitivity and 91% specificity, outperforming fecal immunochemical testing, according to late-breaking data here.
First, second FIT-based screenings 'equally likely' to detect CRC at early stage
Fecal immunochemical test-based screening was effective in detecting early-stage colorectal cancer at first and repeat screenings, with higher FIT cutoff levels having little effect on stage distribution, data showed.
US veteran preference for noninvasive CRC screening highest in West, rose by 19% per year
Veterans who declined participation in a colorectal cancer screening trial more often preferred noninvasive testing over colonoscopy, a preference that increased over time and was especially evident among those in the western United States.
Next-generation Cologuard demonstrates improved colorectal cancer sensitivity, specificity
Next-generation Cologuard exhibited improved colorectal cancer specificity and sensitivity compared with results of the FDA registrational trial that led to approval of the noninvasive screening test, its manufacturer reported.
Offering a blood test as a secondary option boosts CRC screening by nearly twofold
Compared with reoffering colonoscopy and fecal immunochemical test alone, offering a blood test as a secondary option resulted in a nearly twofold increase in colorectal cancer screening in veterans who had declined first-line screening.
CRC screening response suggests a ‘greater opportunity to leverage’ FIT in younger adults
CHICAGO — Individuals aged 45 to 49 years who were mailed fecal immunochemical tests for colorectal cancer screening completed the tests in a timelier manner than those aged 50 years and older, according to data from Digestive Disease Week.
Dedicated patient navigator cost-effective, improved FIT return rates by nearly 38%
CHICAGO — Adding a dedicated patient navigator improved fecal immunochemical testing completion and return rates and resulted in significant savings to the health care system, according to data presented at Digestive Disease Week.